NCT03511963 2024-12-31
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Shanghai Henlius Biotech
Phase 3 Completed
Shanghai Henlius Biotech
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
FeRx